Oct 22 (Reuters) - Guerbet SA GRBT.PA :
* REG-GUERBET: REVENUE AT SEPTEMBER 30, 2020
* AT SEPTEMBER 30, 2020, REPORTED REVENUE WAS EUR 536.0
MILLION
* IS MAINTAINING OBJECTIVES REPORTED WITH ITS HALF-YEAR
RESULTS
* IN COMING MONTHS, GROUP'S ACTIVITY IS EXPECTED TO BE
AFFECTED BY
INITIAL SALES OF GENERIC OF DOTAREM® IN UNITED STATES.
* GUERBET SHOULD CONTINUE TO BENEFIT FROM GOOD PERFORMANCE
OF
LIPIODOL® AND STRENGTH OF XENETIX® AND OPTIRAY®.
* GROUP EXPECTS EBITDA FOR 2020 FINANCIAL YEAR TO BE AROUND
14% OF
REVENUE.
* IS CONFIDENT THAT IT CAN LOWER ITS LEVEL OF STRUCTURAL
COSTS FOR
LONG TERM WITH EXPECTATIONS OF A VERY FAVORABLE IMPACT ON
PROFITABILITY ONCE BUSINESS IS BACK TO NORMAL.
Source text for Eikon: [ID: nGNX6ZqKgp]
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))